Sponsored Videos

Chris Dowd and Lisa Prowker of ConnectiveRx discuss point-of-care marketing as the key activation layer for investments in patient access and support—it’s essential for converting dollars spent in payer negotiations and copay programs into prescriptions.

Valerie Bandy and Ryan Rotar, both from Tecsys, examine how hospital pharmacy leaders are reshaping their expectations and prioritizing value-driven partnerships over traditional transactional vendor relationships. They explore the growing shift toward self-distribution and direct purchasing, as well as how transparency and proactive communication are now essential to mitigating logistics risk and safeguarding patient care. This interview stresses technology’s role as a critical enabler of data visibility, empowering manufacturers to build long-term trust through consistent performance and shared accountability.

Discover how AI-powered patient intelligence is ushering in a new era of pharma leadership defined by clarity, speed, and knowing the “why” behind every shift.

Understand how real-time patient intelligence transforms leadership conversations from speculation and opinion battles into confident, data-backed strategy.

Learn how outdated or incomplete insights turn every decision into a high-stakes gamble that cost brands money, momentum, and internal alignment.

David Edelman, Founder & CEO of Thrivable, provides an unflinching look at why today’s most relied-upon tools, including syndicated data, social listening, gut instinct, still leave leaders navigating with a blurry, incomplete map.

This episode acts as a peek inside the modern pharma boardroom, where leaders are expected to defend billion-dollar brands with data that’s too slow, too vague, and too outdated to survive today’s market velocity.

This series kicks off by introducing David Edelman, Founder & CEO of Thrivable, who joins Pharmaceutical Executive to discuss the rising “clarity gap” that is currently putting pharma leaders under pressure.

Discover how agentic AI is reshaping life sciences commercial operations.

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and access strategies as payers balance real-world evidence with head-to-head clinical trials in their decision-making.

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.

A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based endpoints to ensure successful access, pricing, and long-term market viability—especially in a more complex, globally integrated reimbursement landscape.

Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping market access strategy, stressing the importance of early planning and the urgency of ensuring that innovative therapies are available and affordable for patients.

Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus™ Access and Patient Support, outlines the recent shift in the patient services industry towards a hybrid hub model for in-house management and outsourced support.

Rob Truckenmiller, CEO of PharmaCord, talks about the company’s role in patient services, trends he sees shaping patient access to healthcare in the U.S., and a recent patient-centric merger.

Kapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients have easier access to healthcare information, and the exciting future of pharmaceutical manufacturing and patient care.

How the 2028 Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care

Our network connects providers, health plans, and life science companies to deliver seamless care that benefits everyone

Joseph Panetta, President and CEO of Biocom California, shares his insights on biotech industry trends, policy challenges, and educational initiatives, drawing from over 25 years of leadership in California’s thriving life sciences sector.

Max Colao, CEO of OncoVerity, discusses his extensive experience in the biotech industry and shares how his company is harnessing computational biology and machine learning to develop personalized cancer treatments that aim to reshape the future of oncology care.

Elyse Blazevich discusses the Colorado Bioscience Association’s efforts to support the state’s life sciences sector by fostering partnerships, advocating for industry growth, and building a diverse talent pipeline.

In this interview, Melissa Krebs,Ph.D., CEO and founder of GelSana, shares her journey in developing cutting-edge biomaterials that could transform the $78 billion wound care market.

Dr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific, covers key considerations for choosing registries.

How a multipronged approach to staff recruitment can accelerate trial success.